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Multidrug resistance (MDR) in cancer cells is a substantial limita-
tion to the success of chemotherapy. Here, we describe facile means
to overcome resistance by silencing the multidrug resistance protein
1 (MRP1), before chemotherapeutic drug delivery in vivowith a single
local application. Our platform contains hydrogel embedded with
dark-gold nanoparticles modified with 5-fluorouracil (5-FU)-interca-
lated nanobeacons that serve as an ON/OFF molecular nanoswitch
triggered by the increasedMRP1 expression within the tumor tissue
microenvironment. This nanoswitch can sense and overcome MDR
prior to local drug release. The nanobeacons comprise a 5-FU inter-
calated DNA hairpin, which is labeled with a near-infrared (NIR) dye
and a dark-quencher. The nanobeacons are designed to open and
release the intercalated drug only upon hybridization of the DNA
hairpin to a complementary target, an event that restores fluores-
cence emission due to nanobeacons conformational reorganization.
Despite the cross-resistance to 5-FU, more than 90% tumor re-
duction is achieved in vivo in a triple-negative breast cancer model
following 80%MRP1 silencing comparedwith the continuous tumor
growth following only drug or nanobeacon administration. Our ap-
proach can be applied to reverse cross-resistance to other chemo-
therapeutic drugs and restore treatment efficacy. As a universal
nanotheranostic probe, this platform can pave the way to early
cancer detection and treatment.
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multidrug resistance
Multidrug resistance (MDR) in cancer is a phenomenonwhereby cancer cells gain the capacity to develop cross-
resistance and survive a variety of structurally and functionally
unrelated drugs (1). The most commonMDRmechanisms occur by
the expression of one or more energy-dependent transporters,
which can result in an increased efflux of the cytotoxic drugs from
the cancer cells, thus lowering their intracellular concentrations (2).
The phosphoglycoprotein multidrug resistance protein 1 (MRP1 or
ABCC1) is often associated with resistance to a broad spectrum of
anticancer drugs and belongs to the ATP-binding cassette (ABC)
superfamily of proteins as energy-dependent efflux pumps (3). The
ABC transporters are essential not only to breast cancer MDR but
also to other types of cancer, such as non–small cell lung cancer, lung
cancer, and rectal cancer (4). In fact, increased ABC expression
levels have been shown to correlate with decreased response to
various chemotherapy drugs [such as 5-fluorouracil (5-FU)] and
a decrease in overall survival (5). 5-FU is widely used in cancer
therapy as it has the capacity to interfere with nucleoside metab-
olism and result in DNA and RNA synthesis disorders and dys-
function, leading to cytotoxicity and cell death. Based on the
American Cancer Society guidelines, 5-FU is used to treat a range
of cancerous diseases, including colon and rectal cancer; breast
cancer; gastrointestinal cancers including anal, esophageal, pan-
creas, and gastric (stomach); head and neck cancer; and ovarian
cancer. For decades, 5-FU has been used in combination with other
antineoplastic agents or as a single agent in the adjuvant and pal-
liative treatment of advanced breast cancer (6). Nevertheless, the
overall response to this drug remains only 15% due to resistance
mechanisms (7). Hence, despite the remarkable progress in che-
motherapeutic drug development in the last decade, ∼70% of
cancer patients do not respond to chemotherapy and have a 5-y
survival rate of 10–30% (8). Consequently, new platforms that are
able to improve antitumor efficacy are urgently needed.
The development of nanoscale devices has provided major
breakthroughs in cancer diagnostic and therapy (9–13), especially
in drug delivery (14, 15). Because nanoparticles are excellent
tumor-targeting vehicles due to enhanced permeability and re-
tention (EPR) in the tumor microenvironment (having defective
vasculature and poor lymphatic drainage) (16, 17), they can be
harnessed to alter MDR mechanisms. Indeed nanomaterials have
been used to help overcome MDR by increasing drug retention in
cancer cells and hamper cancer progression (7, 18–20). Neverthe-
less, a platform that senses and inhibits MDR gene expression
followed by selective drug release has not been reported yet.
Here we developed a universal nanodevice able to sense specific
gene sequence, silence it, and release a chemotherapeutic drug,
while reporting on these events. A bioresponsive hydrogel-nanop-
robe that locally senses and inhibits the expression of the MRP1,
followed by subsequent release of 5-FU drug to resistant triple-
negative breast cancer cells (TNBC), was developed. Breast can-
cer was chosen as a model because it can benefit from local non-
invasive administration of an injectable hydrogel. TNBC accounts
for 15–20% of all breast cancers, and it represents the most ag-
gressive subtype with a direct prognosis. TNBCs are characterized
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by resistance to apoptosis, aggressive cellular proliferation, mi-
gration and invasion, and currently lack molecular markers and
effective targeted therapy. TNBC patients suffer from poor sur-
vival rates and limited efficacy of neoadjuvant chemotherapy, as
tumors from such patients are characterized by overexpression of
specific genes involved in drug-desensitizing mechanisms (21). We
now show that smart bioresponsive hydrogel-nanoprobes are able
to reduce 5-FU drug-resistant tumors by 90% 14 d after hydrogel
implantation in breast cancer tumor-bearing mice by silencing
more than 80% of MRP1 expression before drug release. This
approach can be applied to improve treatment efficacy using other
chemotherapeutic drugs for a range of solid tumors.
Results and Discussion
Bioresponsive Dark-Gold Nanoswitch Design. Our nanoprobe en-
compasses a gold nanoparticle (AuNP) core decorated with a
thiol-DNA hairpin labeled with a near-infrared (NIR) dye
(intercalated with a chemotherapeutic drug, 5-FU) and a thiol-
DNA oligo labeled with a Black-Hole dark quencher (Fig. 1A),
which is used as a two-pair FRET/nanosurface energy transfer
(NSET) donor quencher nanoconjugate for universal cancer gene
therapy and drug delivery. Polyethylene glycol (PEG) is also used as
a spacer between the hairpins, increasing their nanostructure sta-
bility in biological medium (22–24) (see SI Appendix, Fig. S1 for
PEG optimization and quantification). Thiol-DNA oligo labeled
with a dark quencher is used to quench nanobeacon fluorescence.
Under hairpin configuration, the proximity of the NIR dye (Quasar
705) to the dark quencher (BHQ2) leads to fluorescence quenching.
Hybridization of the DNA hairpin to a complementary target (i.e.,
MRP1 mRNA) restores fluorescence emission due to the gold
nanobeacon conformational reorganization that causes the fluoro-
phore and the quencher to part from each other, yielding a quan-
titative response.
The mechanism of mRNA knockdown in this study is based on
antisense DNA technology (25). This method was used to inhibit
or down-regulate the production of MRP1 protein by using an-
tisense DNA oligonucleotides, the DNA molecular beacon anti-
MRP1, which precisely complements the MRP1 mRNA target
sequence present in the cell. These molecular beacons have the
ability to interlock or hybridize with the target MRP1 mRNA
(blocking specific translation initiation signals of MRP1 gene),
thus inhibiting the translation of the target protein. Oligomers
sequences and 2D structures of the beacons at 37 °C are depicted
in SI Appendix, Table S1 and Fig. S2A, respectively.
The release of the 5-FU drug is designed to occur only when
DNA hairpin hybridizes with the complementary mRNA target
inside the cell and can be tracked fluorescently once the distance
between 5-FU and the gold core increases upon drug release.
The 5-FU wedge between bases along the dsDNA part of the
nanobeacon. The drug covalently binds to DNA in different sites
producing intrastrand cross-links, preventing the polymerase and
other DNA binding proteins from functioning properly, which
results in DNA synthesis, inhibition of transcription, and in-
duction of mutations. The choice of fluorophores and quenchers
enabled the gold nanobeacon with BHQ2 dark quencher, which
extends to the near-infrared emission wavelengths, to overlap
with the absorbance range of the Quasar 705 fluorophore, and
the surface plasmon resonance (SPR) profile from gold nano-
beacon to overlay the absorbance wavelength from the 5-FU at
450 nm (SI Appendix, Fig. S2B). The BHQ2 group functioned
as quencher for the Q705 (donor 1) and the AuNPs functioned
as the quenchers for the 5-FU (donor 2). The NIR dye and dark
quencher, Quasar 705nm (Q705) and BHQ2 (26) (Black Hole
Quencher-2 with a strong absorption from 599 to 670 nm), were
chosen to enable efficient quenching in the nanobeacon basal
state with restored fluorescence upon conjugation to the ap-
propriate target. The fluorescence emission from the 5-FU
(Emi = 450 nm) is efficiently quenched by the ∼14-nm AuNP
due to the NSET effect (27). This NSET effect provides the dark-
gold nanobeacons with the ability to serve as an on/off switch.
This capability is particularly useful for tracking drug release in
response to a specific gene expression within the tumor micro-
environment. These events, binding to a target and the resulting
drug release, are each reported by fluorescence emission in a
defined wavelength.
In addition to designing an anti-MRP1 nanobeacon that
detects and inhibits MRP1 mRNA, anti-Luc nanobeacons (that
hybridize with luciferase mRNA and release the drug without
targeting MRP1) and nonsense nanobeacons (that do not hy-
bridize with any target) were developed as controls (SI Appendix,
Fig. S2A and Table S1).
Transmission electron microscopy (TEM) images of the dark-
gold nanobeacons loaded with 5-FU showed an average di-
ameter ± SD of the gold core of 13.8 ± 3.4 nm (SI Appendix,
Fig. S2C). The final Q705 DNA hairpin:NP and BHQ2 oligo:
NP ratios were approximately 30:1 and 24:1, respectively. The
ratio for 5-FU:NP was 100:1 (SI Appendix, Table S2). The mean
particle diameter ± SD of dark-gold nanobeacons is 25.5 ± 1.2
nm without 5-FU and 31.1 ± 0.5 nm loaded with 5-FU, with an
SPR peak around 548–550 nm as measured by dynamic light
scattering (DLS) and UV-Vis extinction profiles, respectively
(Fig. 1D and SI Appendix, Table S2).
The fluorescence is OFF when the hairpin-DNA-Q705 is closed
(i.e., no hybridization with the complementary target), inhibiting
5-FU release (Fig. 1A). The fluorescence is ON when the hairpin-
DNA-Q705 hybridizes with a complementary target and an in-
crease in Q705 emission occurs, with a concomitant 5-FU release
and increase in the drug emission (Fig. 1A). It is worth noting that
the fluorescence emission intensity of Q705-labeled DNA oligo is
significantly decreased following their conjugation to the dark-
gold nanoparticles. The binding between the Q705-labeled DNA
oligo and the dark-gold nanoparticles occurs by a direct quasi-
covalent bond between the thiol group on the 5′ end of the oligo
and the gold surface by ligand-exchange between the citrate
groups on the surface of the AuNPs and thiol groups. When the
concentration of Q705-labeled DNA oligo was fixed at 0.5 μM, the
increase in dark-gold nanobeacons concentration from 0 to 10 nM
in the reaction mixture resulted in a significant increase in Q705
fluorescence quenching (Fig. 1B), demonstrating the presence of
NSET between the Q705 groups and the dark-gold nanobeacons.
These experimental data showed a quenching efficiency of nearly
99% when the concentration of dark-gold nanobeacons reached
1 nM, whereas it was nearly 100% when the concentration of
AuNPs reached 2.5 nM. These data confirm that the combination
of BHQ2 oligo and attachment to the surface of gold nanobeacons
provides powerful fluorescence quenching for Q705 emission. The
same phenomenon occurs for 5-FU loading on dark-gold nano-
beacons (Fig. 1C). When 1 mM 5-FU was loaded on 2.5 nM dark-
gold nanobeacons, the fluorescence emission spectra of 5-FU after
incubation in phosphate buffer (pH 7.0, 10 mM) for different
periods of time (0–120 min) confirmed a significant increase in
5-FU fluorescence quenching (Fig. 1C). This phenomenon indeed
indicated the formation of dark-gold nanobeacons loaded with
5-FU. Conversely, the Q705 emission can be restored after hy-
bridization with the complementary ssDNA target. Increasing
amounts of complementary target results in elevated emission
form the Q705 dye until reaching a plateau at 1 μM of target (Fig.
1D) and in 5-FU release, with nearly complete drug release at
1 μM of target (Fig. 1E). We studied the release kinetics of the
intercalated drug following fluorescence of the 5-FU that was
measured for 75 min following addition of 1 μM of target and
compared it with the fluorescence of the Q705 (SI Appendix, Fig.
S3). As expected, the kinetics of the 5-FU release follows that of
nanobeacons opening subsequent to the hybridization of a fully
complementary target.
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The stability of dark-gold nanobeacons loaded with 5-FU toward
variations in temperature, pH, DNase, and glutathione (GSH)
concentration was also evaluated (SI Appendix, Figs. S4–S7). These
data confirm the stability of the dark-gold nanobeacons loaded
with 5-FU at room and physiological (37 °C) temperatures (SI
Appendix, Fig. S4) and in a wide pH range (4.5–8) (SI Appendix,
Fig. S5), as well as intracellular concentrations of GSH (SI Ap-
pendix, Fig. S6) and DNase (SI Appendix, Fig. S7).
MRP1 Triggered 5-FU Release in Vitro. To test the ability of dark-
gold nanobeacons loaded with 5-FU to overcome MDR, nano-
beacons intracellular uptake and trafficking was examined us-
ing a 5-FU–resistant MDA-MB-231 breast cancer cell line
obtained by continuous culturing of parental MDA-MB-231
cells in a 0.05-mg/mL dose of 5-FU. Drug resistance was con-
firmed by the absence of cell death using the [3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide] (MTT) assay
Fig. 1. Dark-gold nanobeacons designed to sense and overcome cancer multidrug resistance. (A) AuNPs (14 nm) functionalized with PEG, a thiol-DNA hairpin
labeled with a NIR dye and a thiol-DNA oligo labeled with a dark quencher. These dark-gold nanobeacons are then loaded with 5-FU that intercalates in the
beacon stem (dsDNA part) of the DNA hairpin oligo. Dark-gold nanobeacons are designed to silence the expression ofMRP1 and deliver at the same time the
chemotherapeutic drug 5-FU, to circumvent essential MDR mechanisms. The AuNPs and the BHQ2 groups functioned as the quenchers and the Q705 and 5-FU
as the donors. The fluorescence is OFF when the hairpin-DNA-Q705 is closed (i.e., no hybridization with the complementary target), and therefore no
consequent 5-FU release occurs. The fluorescence is ON when the hairpin-DNA-Q705 hybridizes with a complementary target and an increase in Q705
emission occurs, with a concomitant 5-FU release and increase in the drug emission. (B) Fluorescent intensity change of Q705 (0.5 μM) after reaction with dark-
gold nanobeacons at different concentration from 0 to 10 nM. Excitation wavelength = 675 nm. (C) Fluorescence emission spectra of 5-FU (1 mM) after
incubation with 2.5 nM of dark-gold nanobeacons-Q705 for different periods of time (0–120 min). Q705 (D) and 5-FU (E) emission spectra after hybridization
of nanobeacons anti-MRP1 and nonsense with increasing amounts of the complementary and noncomplementary ssDNA target (0–5 μM).
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after continuous exposure to drug compared with parental can-
cer cells (SI Appendix, Fig. S8).
Dark-gold nanobeacons could enter and accumulate in re-
sistant MDA-MB-231 cells as verified by confocal microscopy,
showing specific targeting at 48-h incubation of anti-Luc and
anti-MRP1 nanobeacons compared with nanobeacon nonsense
(that do not hybridize with any target). It is evident that silencing
occurs only with anti-Luc and anti-MRP1 nanobeacons because
hairpin conformational change due to specific hybridization to
the target sequence can be identified via fluorescence emission
(Fig. 2A). Epi-fluorescence images of cellular uptake kinetics of
cells incubated with anti-MRP1 nanobeacons for 0.5, 2, 4, 8, 24,
and 48 h are depicted in SI Appendix, Fig. S9. Nanobeacons
cellular uptake and detection associated with drug release signal
for the same time points are depicted in SI Appendix, Fig. S10.
Indeed, analytical flow cytometry data confirmed the phenomena
observed via confocal imaging of a substantial increase in Quasar
705 signal only for nanobeacons anti-Luc and anti-MRP1 com-
pared with nanobeacon nonsense (Fig. 2B).
Confocal images of breast cancer cells further revealed that
the dark-gold nanobeacons anti-MRP1 were colocalized in intra-
cellular organelles such as endosomes and/or lysosomes at 24 h
and could escape out of this organelles at 48 h (Fig. 2C).
Overcoming Intracellular 5-FU Resistance. To corroborate confocal
and flow cytometry data and overcome 5-FU resistance, resistant
MDA-MB-231 cells were incubated with increasing amounts of
dark-gold nanobeacons with and without 5-FU and evaluated by
the live imaging system. As expected, only anti-Luc and anti-
MRP1 nanobeacons loaded with 5-FU can produce a substantial
decrease in luminescence (Fig. 3A, also see SI Appendix, Fig. S11
for luminescence and fluorescence signal quantification). The
same occurs for cell viability evaluated by MTT assay (Fig. 3 B and
C). Dark-gold nanobeacons without 5-FU do not affect cell via-
bility (Fig. 3B) compared with the dark-gold nanobeacons loaded
with 5-FU, with an IC50 near 0.5 nM (Fig. 3C) at 72 h of exposure.
Live-dead staining of resistant MDA-MB-231 cells after up-
take of increasing concentrations (0.1, 1, and 5 nM) of dark-gold
nanobeacons for 48 h was performed using a double staining
procedure with acridine orange (AO) and propidium iodide (PI)
representing green and red fluorescence for live and dead cells,
respectively. As shown in Fig. 3D, only nanobeacon anti-MRP1
loaded with 5-FU (at 5 nM) results in extensive cell death
(>95%), due to the combination of MRP1 inhibition and con-
sequent drug (5-FU) release. Nanobeacon anti-Luc shows mod-
est cell death despite releasing the drug as MRP1 inhibition does
not occur (see SI Appendix, Fig. S12 for in vitro real-time PCR
data) becauseMRP1 can actively pump cytotoxic drugs like 5-FU
Fig. 2. (A) Representative confocal images of resistant MDA-MB-231 cells incubated for 48 h with a nanobeacon nonsense, nanobeacon anti-Luc, and
nanobeacon anti-MRP1 (5 nM). (Scale bars, 20 μm.) (B) Flow cytometry analysis comparing nanobeacon anti-Luc and nanobeacon anti-MRP1–treated cells
to nanobeacon nonsense. (C) Intracellular colocalization of nanobeacon anti-MRP1 within lysosomes. Resistant MDA-MB-231 cells were treated with 5 nM
nanobeacon anti-MRP1 (in red) for 24 and 48 h, and lysosomes (in green) were stained with Lysotracker Green DND26. Overlap of nanobeacon anti-MRP1 and
lysosome marker is represented in yellow in the merged images.
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from the cytosol across the plasma membrane at the expense of
ATP (28).
To evaluate the kinetics of the 5-FU effect and the mRNA
MRP1 knockdown by the nanobeacons, an MTT cell viability
assay was performed after 24, 48, and 72 h and compared with
the kinetics for MRP1 expression using 5 nM (the same con-
centration for in vitro and in vivo studies) of nanobeacons loaded
with 5-FU (SI Appendix, Fig. S13). These data corroborate that
the maximum mRNA knockdown (at 48 h) occurs 24 h before
the maximum effect of the drug (at 72 h), showing that the 5-FU
is mostly effective 24 h after the drug reversal mechanism
takes place.
Hydrogel-Gold Nanoswitch Sensing and Targeting in Vivo. To eval-
uate the efficiency of the dark-gold nanobeacon probes in
sensing and in overcoming MDR in vivo, an orthotopic breast
cancer mouse model was developed by injecting resistant MDA-
MB-231 cells to the mammary fat pad of female SCID hairless
congenic mice. Efficacious and local delivery of the dark-gold
nanobeacon probes is achieved by the implantation of a hydrogel
disk on top of the triple-negative breast tumors (Fig. 4A). The
hydrogel scaffold comprising a polyamidoamine (PAMAM G5)
dendrimer cross-linked with dextran aldehyde provides enhanced
stability of the embedded nanoparticles. Epi-fluorescence images
show a homogeneous distribution of the dark-gold nanobeacon
probes (previously hybridized with a complementary target) in
the hydrogel network (Fig. 4 B and C). The dual labeling dis-
closes a colocalization of the nanobeacon probes (red) and the
tagged polymeric matrix (green) that can be attributed to elec-
trostatic interaction between the nanobeacons and the hydrogel
(Fig. 4C and SI Appendix, Fig. S14). This reversible interaction
enables rapid local release of the nanoparticles at the site of
interest, as demonstrated by the almost complete release in the
first 24 h under physiological conditions in vitro (pH 7.4 and
37 °C; SI Appendix, Fig. S15). This local delivery platform using
dextran-dendrimer hydrogel scaffolds (29–31) overcomes some
of the limitations associated with systemic administration, such
as low stability, dissociation form vector, and short lifetimes (32).
Additionally, local delivery prevents the uptake of systemically
administered nanoparticles by the liver that makes targeting to
other organs difficult. Once tumors reach a desired volume
(∼100 mm3), hydrogel scaffolds loaded with dark-gold nano-
beacon probes are implanted adjacent to the mammary fat pad
tumor. Over a period of 14 d following hydrogel implantation, in
vivo imaging was used to simultaneously track tumor inhibition as
measured by luciferase expression (Fig. 4D), nanobeacon probes
(Fig. 4E) before and after hybridization to MRP1 mRNA, and
hydrogel stability monitored by FITC fluorescence emission. No
signs of inflammation were observed at the surgical site, and there
were no changes in body weight following hydrogel implantation (SI
Appendix, Fig. S16), suggesting that hydrogels are biocompatible,
with no associated toxicity or side effects. Bioluminescence imaging
of mice revealed that only nanobeacon anti-MRP1 loaded with
Fig. 3. (A) Fluorescence (in red) and luminescence signals of resistant MDA-MB-231 cells incubated with increasing amounts (0.1–5 nM) of dark-gold
nanobeacons loaded without and with 5-FU. MTT assay of resistant MDA-MB-231 cells incubated for 72 h with increasing amounts of dark-gold nanobeacons
without (B) and with (C) 5-FU. (D) Live-dead staining of resistant MDA-MB-231 tumor cells after uptake with 0.1, 1, and 5 nM of dark-gold nanobeacons (red,
dead cells; green, live cells). (Scale bars, 25 μm.)
E1282 | www.pnas.org/cgi/doi/10.1073/pnas.1421229112 Conde et al.
5-FU was able to promote efficient and sustained inhibition of tu-
mor progression (Fig. 4D), with an ∼90% tumor size reduction 14 d
after hydrogel disk implantation. Representative images of whole
body organs and resected tumors in mice treated with nanobeacons
are depicted in SI Appendix, Fig. S17, corroborating the significant
tumor size reduction 14 d after hydrogel implantation. Interestingly,
in vivo hydrogel degradation as monitored by FITC intensity (SI
Appendix, Fig. S18) coincided with nanobeacon fluorescence,
showing the highest signals during the first 2 d, in which the hy-
drogel degrades, and reaching about 45–50% degradation after 14 d.
Monitoring the change in tumor size as a function of time after
treatment with nanobeacons revealed a significant reduction in
Fig. 4. Fluorescently labeled scaffolds loaded with dark-gold nanobeacons are implanted adjacent to the mammary fat pad tumor in mice. (A) Cryosection of
dendrimer:dextran adhesive hydrogel (12 μm thickness) depicting adhesive morphology (dextran aldehyde was tagged with fluorescein). (B) Cryosection of
anti-MRP1 nanobeacon-doped dendrimer:dextran scaffold. (C) Cryosection of anti-MRP1 nanobeacon (previously incubated with the complementary target
MRP1)-doped dendrimer:dextran scaffold. Nanobeacons (red) are uniformly distributed in the hydrogel scaffold (green). (D and E ) IVIS imaging of female
SCID mice xenografted with triple-negative breast tumors implanted with hydrogels embedded with nanobeacon anti-MRP1 with and without 5-FU,
a nanobeacon anti-Luc with 5-FU, nanobeacon nonsense with 5-FU, and free drug (5-FU only). Representative imaging of individual mice from each treated
group (n = 5 animals) is shown, with the same scale of photon flux indicating luciferase activity (D) and epi-fluorescence from the dark-gold nanobeacons
Q705 signal (E). Ex vivo images of breast tumors for each group are also represented. (F) Evaluation of change in tumor size as a function of time after
treatment with nanobeacons (n = 5, ***P < 0.005). (G) Nanobeacon probes (embedded in hydrogel) signal as a function of time after treatment with
nanobeacons (n = 5, ***P < 0.005).
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tumor growth (n = 5, P < 0.005) at day 14 after NP treatment
(Fig. 4F), with almost complete tumor regression only for the
nanobeacon anti-MRP1 loaded with 5-FU group. About 90%
decrease in luciferase activity (Fig. 4F) and in tumor size (SI
Appendix, Fig. S17) was observed exclusively for the nano-
beacon anti-MRP1 loaded with 5-FU–treated tumors com-
pared with free drug (5-FU only), anti-MRP1 only, anti-Luc
loaded with 5-FU, and nanobeacon nonsense with 5-FU (n = 5,
P < 0.005). The free drug has no effect as expected because the
cells are resistant to 5-FU. Only when we silence MRP1 with the
nanobeacon anti-MRP1 does the drug become effective again.
Concerning nanobeacon probe imaging, images of implanted
hydrogels revealed that the fluorescent signal is OFF at day
0 (2 h after surgery) and is turned ON at day 1 (24 h), reaching
a maximum intensity for MRP1 and luciferase detection at day
2 (48 h) only for nanobeacon anti-MRP1 with and without 5-FU
and for nanobeacon anti-Luc loaded with 5-FU, respectively
(Fig. 4G).
Ex Vivo Tumor Characterization and Biodistribution. Ex vivo organ
biodistribution of nanobeacons at day 14 showed remarkable
accumulation in the tumor (Fig. 5A), with no unspecific accu-
mulation in the other main organs. In fact, ∼40% of the nano-
beacon probes persisted in the tumoral tissue (Fig. 5A). These
data confirm the specificity of this platform in vivo, not only for
sensing but specifically to overcome MDR in breast tumors. To
confirm the observed in vivo effects, gene expression analysis of
resected tumors was conducted to verify silencing of MRP1, as
silencing of an important MDR gene would impart a sub-
stantially higher intracellular concentration of the chemothera-
peutic drug. Indeed, real-time PCR results showed a decrease in
MRP1 expression in both nanobeacon anti-MRP1 loaded with
Fig. 5. (A) Epi-fluorescence images of whole body organs confirms selective accumulation of the dark-gold nanobeacons in tumors. (B) Evaluation of MRP1,
VEGF, and EGFR expression via real-time PCR of tumors after treatment with nanobeacon anti-MRP1 (➋), nanobeacon anti-MRP1 with 5-FU (➌), nanobeacon
anti-Luc with 5-FU (➍), and nanobeacon nonsense with 5-FU (➎), using GAPDH as the reference gene. (C) H&E stains of treated groups in hydrogels embedded
with different nanobeacons, in mice bearing xenografts tumors. (D) Immunohistochemical evaluation of tumors treated with hydrogels embedded with
nanobeacon anti-MRP1 with 5-FU (➌) and with nanobeacon anti-Luc with 5-FU (➍) for VEGF and vessel density (CD31).
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and without 5-FU.MRP1 is a cell surface efflux pump involved in
the redox regulation of MDR by reducing the intracellular con-
centration of 5-FU, making this a clinically relevant biomarker for
triple-negative breast cancer. Nevertheless, expression of vascular
endothelial growth factor (VEGF) and epidermal growth factor
receptor (EGFR) decreases only after treatment with nano-
beacon anti-MRP1 loaded with 5-FU (Fig. 5B). H&E staining of
breast tumor sections showed evidence of extensive reduction in
vascularization for nanobeacon anti-MRP1 loaded with 5-FU only
(Fig. 5C), in accordance with tumor size reduction due to over-
coming drug resistance. Immunohistochemical analysis showed
that the expression of VEGF and the number of microvessels
(CD31) were reduced only after treatment with hydrogels em-
bedded with nanobeacon anti-MRP1 with 5-FU (Fig. 5D). An
increasing number of large vessels can be found in the control
groups compared with nanobeacon anti-MRP1 with 5-FU. The
combination of specific tumor accumulation of these nanoparticles
and their imaging properties represents an exciting opportunity for
the simultaneous sensing and delivery of therapeutic agents for
cancer gene therapy.
Outlook. Intrinsic or acquired multidrug resistance remains
a major obstacle in the management of cancer. Therefore, a
system capable of sensing and targeting MDR genes and able to
overcome drug resistance is of utmost importance in cancer
therapy. Injectable hydrogels placed adjacent to tumor surfaces
have recently been developed and applied for RNAi silencing
(29). Building on these advances, we designed an injectable
hydrogel doped with gold nanobeacons as a smart ON/OFF
molecular nanoswitch. This universal theranostics probe enables
sensing and targeting of a specific multidrug resistance gene and
selective delivery of a chemotherapeutic drug to triple-negative
breast cancer tumors in vivo. The nanoswitch is ON only when
detecting MRP1 in the cell, a process that triggers concomitant
drug release following nanobeacon opening. Silencing MRP1
enables the reprogramming of resistant cancer cells to restore
sensitivity to specific chemotherapeutic agents. A single appli-
cation of this nanoswitch embedded in the hydrogels produced
effective and sustained detection and gene silencing in breast
tumors for at least 14 d with active drug release. Our nano-
device produces significant levels of gene knockdown and re-
markable tumor size reduction. The approach taken in this
study can be exploited to detect and inhibit any gene of interest
in light of its endogenous expression in the tumor milieu, fol-
lowed by the delivery of any choice of intercalated drug.
Materials and Methods
Synthesis of Bare-Gold Nanoparticles. Gold nanoparticles, with an average
diameter of 13.8 ± 3.4 nm, were synthesized by the citrate reduction method
described by Lee and Meisel (33). Briefly, 225 mL of 1 mM hydrogen tetra-
chloroaureate (III) hydrate (Sigma) (88.61 mg) was dissolved in 500 mL of
distilled water, heated, and stirred under reflux. When the solution boiled,
25 mL of 38.8 mM sodium citrate dihydrate (Sigma; 285 mg) was added,
resulting in a red solution. The solution was kept under ebullition with vig-
orous stirring and protected from light for 30 min. The solution was allowed
to cool down and was kept protected from light. Bare-gold nanoparticles
were characterized by TEM and UV-Vis molecular absorption spectra.
Synthesis of PEGylated-Gold Nanoparticles. Functionalization of PEGylated
gold nanoparticles was carried out using commercial hetero-functional PEG
functionalized with a 30% (wt/vol) saturated surface of α-mercapto-
ω-carboxy PEG olution (HS-C2H4-CONH-PEG-O-C3H6-COOH; molecular weight,
3,500 Da; Sigma) as described elsewhere (34, 35). The 30% saturated PEG layer
allows the incorporation of additional thiolated components, such as the thio-
lated DNA-hairpin-Quasar 705 nm and the tiolated-oligo-BHQ2 quencher.
Briefly, 10 nM of the bare-gold nanoparticles was mixed with 0.006 mg/mL of
PEG solution in an aqueous solution of SDS (0.028%). After this, the mixture was
incubated for 16 h at room temperature. Excess PEG was removed by centrifu-
gation (15,000 × g, 30 min, 4 °C) and quantified by amodification of the Ellman’s
Assay (see SI Appendix for complete protocol and quantification methods).
Synthesis of Dark-Gold Nanobeacons. We prepared three different sequences
of gold nanobeacons: a nanobeacon anti-MRP1 (detects and inhibits MRP1
mRNA), a nanobeacon anti-Luc (internal control, hybridizes with luciferase
mRNA and releases the drug; however, does not target MRP1), and a
nanobeacon nonsense (designed to not hybridize with any target within
the genome; SI Appendix, Table S1 for thiol-DNA-hairpin Quasar705 se-
quences). All of these nanobeacons were also functionalized with a DNA-
oligo-BHQ2 dark quencher. Briefly, the thiolated oligonucleotides (Sigma)—
thiol-DNA-hairpin Quasar705 and DNA-oligo-BHQ2 dark quencher—were
suspended in 1 mL of 0.1 M DTT (Sigma), extracted three times with ethyl
acetate, and further purified through a desalting NAP-5 column (GE
Healthcare) using 10 mM phosphate buffer (pH 8) as eluent. Following oli-
gonucleotide quantification via UV/Vis spectroscopy, each oligomer was
added to the AuNP-PEG solution in a 50:1 ratio. AGE I solution [2% (wt/vol)
SDS, 10 mM phosphate buffer (pH 8)] was added to the mixture to achieve
a final concentration of 10 mM phosphate buffer (pH 8), 0.01% (wt/vol) SDS.
The solution was sonicated for 10 s using an ultrasound bath and incubated
at room temperature for 20 min. Afterward, the ionic strength of the so-
lution was increased sequentially in 50 mM NaCl increments by adding the
required volume of AGE II solution [1.5 M NaCl, 0.01% (wt/vol) SDS, 10 mM
phosphate buffer (pH 8)] up to a final concentration of 10 mM phosphate
buffer (pH 8), 0.3 M NaCl, 0.01% (wt/vol) SDS. After each increment, the
solution was sonicated for 10 s and incubated at room temperature for
20 min before the next increment. Following the last addition, the solution
was left to rest for additional 16 h at room temperature. Then, the function-
alized dark-gold nanobeacons were centrifuged for 20 min at 15,000 × g,
and the oily precipitate was washed three times with MilliQ water and
redispersed in MilliQ water. The resulting dark-gold nanobeacons were
stored in the dark at 4 °C until further use. Characterization of the dark-gold
nanobeacons was performed by DLS (Wyatt Dyna Pro Plate Reader), UV/Vis
spectroscopy, and TEM (SI Appendix, Table S2).
Stability and Specificity Assays for Dark-Gold Nanobeacons. For the detection
of specific targets, 2.5 nM of nanobeacon anti-MRP1 and nanobeacon
nonsense in 10 mM of phosphate buffer, pH 7, was added to 5 nM of
complementary MRP1 target (Sigma). All measurements were performed in
a microplate reader (Varioskan Flash Multimode Reader; Thermo Scientific)
programmed to incubate the reactions for 120 min at 37 °C while recording
the fluorescence intensity every 2 min at an excitation wavelength of 675 nm
for Quasar705-labeled gold nanobeacon and at an excitation of 350 nm for
5-FU. To evaluate whether the reductive cell environment would cause de-
tachment of the thiol-DNA hairpin from the dark-gold nanobeacons, re-
sistance to intracellular concentrations of GST was studied. To mimic the
behavior in the intracellular milieu, 2.5 nM of the nanobeacon anti-MRP1
was incubated with 0.1, 1, 5 (physiological concentration), 10, and 100 mM
GST (Sigma) at 37 °C for up to 120 min, measuring fluorescence intensity
every 2 min (Exc/Emi = 675/705 nm for Quasar705-labeled gold nanobeacon;
Exc/Emi = 350/400 nm for 5-FU). The same procedure described above was
performed for stability at different pHs (4.5, 5.5, 6.5, 7, 7.5, and 8), different
temperatures (25 °C, 37 °C, 42 °C, and 45 °C), and different DNase concen-
trations (0.5, 1, 2.5, and 5 U).
In Vitro Dark-Gold Nanobeacon’s Delivery. MDA-MB-231 cells (from triple-
negative breast cancer) were grown in DMEM (Invitrogen) supplemented
with 4 mM glutamine, 10% heat inactivated FBS (Invitrogen), 100 U/mL
penicillin, and 100 μg/mL streptomycin (Invitrogen) and maintained at
37 °C in 5% CO2. Cells were seeded at a density of 1 × 10
5 cells per well in
24-well plates and grown for 24 h before incubation with nanobeacons.
On the day of incubation, the cells were ∼50% confluent. An MDR breast
cancer cell line MDA-MB-231 was also developed by continuous culture of
parental MDA-MB-231 cells in 5-FU and maintained with 5-FU at a dose of
0.05 mg/mL for 6 wk. After 6 wk, drug resistance was achieved, as was
evident by the absence of cell death via an MTT assay after continuous
exposure to drug compared with parental cancer cells. Briefly, a standard
MTT reduction assay was performed to determine the resistance status of
the cells and the cytotoxicity of the gold nanobeacons. Cells were seeded
at a density of 1 × 105 cells per well in 24-well culture plates in complete
DMEM (500 μL) with serum. After 24 h of exposure, the medium was re-
moved, the cells were washed twice with sterile PBS, and 300 μL of fresh
medium with serum was added. Then 16.7 μL of sterile MTT stock solution
(5 mg/mL in PBS) was added to each well. After incubation for an addi-
tional 2 h, the medium was removed, and the formazan crystals were
resuspended in 300 μL of dimethyl sulfoxide (Sigma). The solution was
mixed, and its absorbance was measured at 540 nm as a working wave-
length and 630 nm as reference using a microplate reader (Varioskan Flash
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Multimode Reader; Thermo Scientific). The cell viability was normalized to
that of cells cultured in the culture medium with PBS treatment. The via-
bility of cells was also visualized by using a double staining procedure with
AO (green, live cells) and PI (red, dead cells). Briefly, 0.5 mL of complete
medium containing 0.67 μM AO and 75 μM PI was added to each well and
was incubated in the dark at 37 °C for 30 min. After rinsing with fresh
medium, live and dead cells were monitored using a fluorescence micro-
scope (Nikon Eclipse Ti). For confocal microscopy, cells were fixed with 4%
(wt/vol) paraformaldehyde in PBS for 15 min at 37 °C and mounted in
ProLong Gold Antifade Reagent with DAPI (Invitrogen) to allow for nu-
clear staining. Images of cells were taken with a Nikon A1R Ultra-Fast
Spectral Scanning Confocal Microscope.
Flow Cytometry. MDA-MB-231 cells incubated with Q705 dark gold nano-
beacons were analyzed, and data were acquired by FACS LSR HTS-2 (BD
Biosciences) flow cytometer.
Quantitative PCR. Total RNA from MDA-MB-231 cells and breast tumors from
SCID mice was extracted using the RNeasy Plus Mini Kit (Qiagen) according to
the manufacturer’s protocol. cDNA was produced using a High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems) using 500 ng of total
RNA. Quantitative RT-PCR was performed with Taqman probes FAM-MGB
for MRP1 (ABCC1) and GAPDH (Applied Biosystems). GAPDH was used as
a reference gene. The reactions were processed using Light Cycler 480 II
Real-time PCR machine (Roche) using TaqMan Gene Expression Master Mix
(Applied Biosystems) under the following cycling steps: 2 min at 50 °C for
uracil N-glycosylase (UNG) activation; 10 min at 95 °C; 40 cycles at 95 °C for
15 s; and 60 °C for 60 s. At least three independent repeats for each ex-
periment were carried out. Gene expression was determined as a fold dif-
ference after normalizing to the housekeeping gene GAPDH.
Development of Orthotopic Triple-Negative Breast Cancer Mouse Model.
Tumors in the mammary fat pad were induced in female SCID hairless con-
genic mice by injection of 5 × 106 resistant MDA-MB-231 cells stably
expressing firefly luciferase, suspended in 50 μL of Hank’s balanced salt so-
lution (HBSS; Lonza). For determination of tumor growth, individual tumors
were measured via caliper, and tumor volume was calculated by tumor
volume (mm3) = width × [length(2)]/2. Treatments began when tumor vol-
ume reached about 100 mm3. All experimental protocols were approved by
the Massachusetts Institute of Technology Animal Care and Use Committee
and were in compliance with National Institutes of Health guidelines for
animal use.
Hydrogel-Dark-Gold Nanobeacon Synthesis and in Vivo Implantation. Dextran
aldehyde was tagged by reaction with fluorescein thiosemicarbazide (Invi-
trogen) in 20 mL of 0.1 M phosphate buffer (pH 7.5) for 30 min at room
temperature. Then, the reaction crude was cooled down in an ice-water
bath, and imine bonds were reduced with 20 mL of 30 mM sodium cyano-
borohydrate in PBS for 30 min. Tagged dextran aldehyde was dialyzed
against double distilled water using a 10,000-Da molecular cutoff filter for
8 d and lyophilized. Tagged hydrogel scaffolds were developed as previously
described (36). Briefly, equal parts of PAMAM G5 dendrimer (Dendritech)
amine of 12.5% (wt/vol) solid content and dextran aldehyde 5% (wt/vol)
solid content with 0.25% fluorescently labeled dextran were mixed to form
6-mm precured disks. For doped scaffolds, nanobeacons were added to the
dendrimer solution before hydrogel formation at a concentration of 20 nM.
All solutions were filtered through a 0.22-μm filter before hydrogel forma-
tion for in vivo implantation. Precured disks of fluorescently labeled scaffold
with or without nanobeacons were formed and implanted peritumorally in
SCID mice.
Hydrogel-Dark-Gold Nanobeacon Fluorescence Imaging. Precured fluorescently
labeled scaffolds alone (control), doped with nonhybridized and hybridized
nanobeacons, were snap-frozen in liquid nitrogen and kept at −80 °C for
24 h. Then, 12-μm-thick cryosections (Cryostat Leica CM1850) were analyzed
by fluorescence microscopy (NIS-Elements Nikon).
Dark-Gold Nanobeacon Stability in Vitro. Nanobeacons (final concentration,
5 nM) were pretreated with and without complementary target MRP1 and
incubated at 37 °C in dextran and dendrimer solutions [final concentrations of
5% (wt/vol) and 12.5% (wt/vol) in water, respectively]. Samples were collected
at different time points, and fluorescence was measured (Varioskan Flash
Multimode Reader; Thermo Scientific). Fluorescence intensity was plotted
over time.
Hydrogel-Dark-Gold Nanobeacon Release in Vitro. Precured disks of fluo-
rescently labeled hydrogel scaffold doped with hybridized nanoparticles
were incubated in PBS at 37 °C. At different time points, samples were
collected from the PBS, and the fluorescence of released products was
quantified (Varioskan Flash Multimode Reader; Thermo Scientific). Data
were plotted as percent nanobeacons/dextran aldehyde released for each
time point. Controls for this experiment included scaffold without nano-
beacons and scaffold with nonhybridized nanobeacons.
Analysis of Tumor Growth and Hydrogel-Gold Nanobeacon Degradation. Non-
invasive longitudinal monitoring of tumor progression was followed by the
luminescent signal from theMDA-MB-231 cells (n= 5 animals per treated group)
using IVIS Spectrum imaging system (Xenogen XMP-2 Corporation). Fifteen
minutes before imaging, mice were administered with 150 μL of D-luciferin
(30 mg/mL; Perkin-Elmer) in Dulbecco’s phosphate-buffered saline (DPBS) via
i.p. injection. Whole-animal imaging was performed at the indicated time
points: days 0 (2 h after gel implantation), 1, 2, 4, 7, and 14. Assessment of in
vivo toxicity via mice body weight evaluation was performed on all of the
animal groups for 37 d after hydrogel-gold nanobeacon exposure.
Statistics. Differences between groups were examined using the Student
paired t test through the SPSS statistical package (version 17; SPSS Inc.). All
error bars used in this report are mean ± SD of at three independent ex-
periments. All in vivo experiments used five mice per treatment group unless
noted otherwise.
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